Daily non-political popular news in brief.

Anti-dandruff compound may help fight epilepsy

Researchers at Johns Hopkins have discovered that the same ingredient used in dandruff shampoos to fight the burning, itching and flaking on your head also can calm overexcited nerve cells inside your head, making it a potential treatment for seizures. Results of the study can be found online in Nature Chemical Biology.

Read more »

Keywords: anti-dandruff, compound, fight, epilepsy, anti, dandruff

« Previous | Next »

Similar news on "Anti-dandruff compound may help fight epilepsy":

1. Preclinical study suggests organ-transplant drug may aid in lupus fight
   08-15-2007 · UT Southwestern Medical Center
   A compound related to a drug used in humans to prevent organ-transplant rejection attacks a key biochemical process in the faulty immune cells of lupus-prone mice, suggesting a possible new approach to combating the disease, UT Southwestern Medical Center researchers have found.
   Similar news · Read more »
   
2. Commonplace sugar compound silences seizures
   10-15-2006 · EurekAlert!
   Though in clinical use for decades, a small, sweet-tasting compound is revealing a startling new face as a potential cure for epilepsy
   Similar news · Read more »
   
3. Mercury Compound Found In Fish Damages Pancreatic Cells
   09-29-2006 · ScienceDaily
   Researchers in Taiwan say they have established for the first time that the mercury compound present as a contaminant in some seafood can damage insulin-producing cells in the pancreas.
   Similar news · Read more »
   
4. Shire bioequivalence study results of SPD465, investigational drug for adults with ADHD
   11-16-2006 · EurekAlert!
   Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced that a single once-daily morning dose of the investigational amphetamine compound SPD465, extended release triple-bead mixed amphetamine salts, designed to reduce symptoms of Attention-Deficit/Hyperactivity Disorder in adults for up to 16 hours, was bioequivalent to a dose of ADDERALL XR (mixed salts of a single-entity amphetamine product) followed by a dose of mixed amphetamine salts immediate release ("MAS IR") eight hours later, at the US Psychiatric & Mental Health Congress.
   Similar news · Read more »
   
5. New compound shows promise in halting HIV spread
   01-31-2007 · EurekAlert!
   A new compound has shown promise in halting the spread of HIV by preventing the virus from replicating.
   Similar news · Read more »
   
6. Study confirms imaging compound identifies amyloid-beta in human brain
   03-12-2007 · EurekAlert!
   A team led by Massachusetts General Hospital investigators has confirmed that the imaging agent Pittsburgh Compound B (PiB) binds to the protein in amyloid plaques that characterize Alzheimer's disease in the human brain. Their report describes the first postmortem neuropathological study of a dementia patient who had previously participated in a PET imaging study using PiB.
   Similar news · Read more »
   
7. DNA-damage test could aid drug development
   05-14-2007 · EurekAlert!
   Researchers from Massachusetts Institute of Technology and Whitehead Institute have developed a cell culture test for assessing a compound's genetic toxicity that may prove dramatically cheaper than existing animal tests. This assay would allow genetic toxicity to be examined far earlier in the drug development process, making it much more efficient.
   Similar news · Read more »
   
8. MIT model could predict cells' response to drugs
   07-30-2007 · EurekAlert!
   MIT researchers have developed a model that could predict how cells will respond to targeted drug therapies. Models based on this approach could help doctors make better treatment choices and drug developers identify the ideal compound. In addition, the model could help test the effectiveness of drugs for a wide range of diseases, including cancer, arthirtis, and immune system disorders.
   Similar news · Read more »
   
9. Daisies lead scientists down path to new leukemia drug
   10-02-2007 · EurekAlert!
   A new, easily ingested form of a compound that has already shown it can attack the roots of leukemia in laboratory studies is moving into human clinical trials, according to a new article by University of Rochester investigators in the journal, Blood.
   Similar news · Read more »
   
10. Immune compound blocks virus' ability to hijack antibodies
    12-12-2007 · EurekAlert!
    Researchers at Washington University School of Medicine in St. Louis have shown that a controversial phenomenon known as antibody-dependent enhancement of infection is suppressed by C1q, a blood-borne immune system compound. The link may give researchers the lead they need to begin untangling a snarl of evidence from decades of puzzling epidemiological and laboratory-based studies of ADE.
    Similar news · Read more »